Prostate-specific membrane antigen (PSMA)-targeting peptide-drug conjugates (PDCs) offer promise for the treatment of PSMA-positive prostate cancer, but their applications are limited by rapid clearance, poor pharmacokinetics, and low efficacy. This evidence concerns the gene FOLH1 and prostate carcinoma.